Literature DB >> 18000665

Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.

Akihiro Takano1, Christer Halldin, Andrea Varrone, Per Karlsson, Nils Sjöholm, James B Stubbs, Magnus Schou, Anu J Airaksinen, Johannes Tauscher, Balázs Gulyás.   

Abstract

PURPOSE: (S,S)-[(18)F]FMeNER-D(2) is a recently developed positron-emission tomography (PET) radioligand for in vivo quantification of the norepinephrine transporter system. The aim of this study was to provide dosimetry estimates for (S,S)-[(18)F]FMeNER-D(2) based on human whole-body PET measurements.
METHODS: PET scans were performed for a total of 6.4 h after the injection of 168.9 +/- 31.5 MBq of (S,S)-[(18)F]FMeNER-D(2) in four healthy male subjects. Volumes of interest were drawn on the coronal images. Estimates of the absorbed dose of radiation were calculated using the OLINDA software.
RESULTS: Uptake was largest in lungs, followed by liver, bladder, brain and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lung (21.6%ID at 0.3 h), liver (5.1%ID at 0.3 h), bladder (12.2%ID at 6 h) and brain (2.3%ID at 0.3 h). The largest absorbed dose was found in the urinary bladder wall (0.039 mGy/MBq). The calculated effective dose was 0.017 mSv/MBq.
CONCLUSION: Based on the distribution and dose estimates, the estimated radiation burden of (S,S)-[(18)F]FMeNER-D(2) is lower than that of [(18)F]FDG. The radioligand would allow multiple PET examinations in the same research subject per year.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000665     DOI: 10.1007/s00259-007-0622-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

1.  Biodistribution and radiation dosimetry of the dopamine transporter ligand.

Authors:  T A Deterding; J R Votaw; C K Wang; D Eshima; L Eshima; R Keil; E Malveaux; C D Kilts; M M Goodman; J M Hoffman
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

2.  Physical models and dose factors for use in internal dose assessment.

Authors:  Michael G Stabin; Jeffry A Siegel
Journal:  Health Phys       Date:  2003-09       Impact factor: 1.316

3.  Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; J Prince; M Hatch; J Jones; M Harding; S V Faraone; L Seidman
Journal:  Am J Psychiatry       Date:  1998-05       Impact factor: 18.112

4.  Population radiation absorbed dose from nuclear medicine procedures in The Netherlands.

Authors:  H Beekhuis
Journal:  Health Phys       Date:  1988-03       Impact factor: 1.316

5.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

6.  Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.

Authors:  H Berzewski; M Van Moffaert; C A Gagiano
Journal:  Eur Neuropsychopharmacol       Date:  1997-04       Impact factor: 4.600

7.  Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET.

Authors:  Jian-Qiang Lu; Masanori Ichise; Jeih-San Liow; Subroto Ghose; Doug Vines; Robert B Innis
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

8.  Lung as reservoir for antidepressants in pharmacokinetic drug interactions.

Authors:  T Suhara; Y Sudo; K Yoshida; Y Okubo; H Fukuda; T Obata; K Yoshikawa; K Suzuki; Y Sasaki
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

9.  Comparative evaluation of two serotonin transporter ligands in the human brain: [(11)C](+)McN5652 and [(11)C]cyanoimipramine.

Authors:  Akihiro Takano; Tetsuya Suhara; Yasuhiko Sudo; Makoto Inoue; Kenji Hashimoto; Ming-Rong Zhang; Tetsuya Ichimiya; Fumihiko Yasuno; Kazutoshi Suzuki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-27       Impact factor: 9.236

10.  Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects.

Authors:  William Robeson; Vijay Dhawan; Abdel Belakhlef; Yilong Ma; Von Pillai; Thomas Chaly; Claude Margouleff; David Bjelke; David Eidelberg
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

View more
  8 in total

1.  Ex vivo and in vivo evaluation of the norepinephrine transporter ligand [11C]MRB for brown adipose tissue imaging.

Authors:  Shu-fei Lin; Xiaoning Fan; Catherine Weikart Yeckel; David Weinzimmer; Tim Mulnix; Jean-Dominique Gallezot; Richard E Carson; Robert S Sherwin; Yu-Shin Ding
Journal:  Nucl Med Biol       Date:  2012-05-16       Impact factor: 2.408

2.  Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.

Authors:  Xiaofeng Bao; Shuiyu Lu; Jeih-San Liow; Sami S Zoghbi; Kimberly J Jenko; David T Clark; Robert L Gladding; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2012-02-16       Impact factor: 7.446

3.  Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study.

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Per Karlsson; Nils Sjoholm; Stig Larsson; Cathrine Jonsson; Richard Odh; Richard Sparks; Nabil Al Tawil; Anja Hoffmann; Torsten Zimmermann; Andrea Thiele; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 4.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

6.  Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Authors:  Ya-Yao Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Hanna Ng; Jon C Mirsalis; Ying-Kai Fu; Tieh-Chi Chu; Wen-Sheng Huang; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

7.  Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Ralph Paul Maguire; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236

8.  Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.

Authors:  Sho Moriguchi; Harumasa Takano; Yasuyuki Kimura; Tomohisa Nagashima; Keisuke Takahata; Manabu Kubota; Soichiro Kitamura; Tatsuya Ishii; Masanori Ichise; Ming-Rong Zhang; Hitoshi Shimada; Masaru Mimura; Jeffrey H Meyer; Makoto Higuchi; Tetsuya Suhara
Journal:  Int J Neuropsychopharmacol       Date:  2017-12-01       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.